Skip to content
Buy This GLP
← Research
Evidence

Should You Take a GLP-1 for Prediabetes? What the Tirzepatide Trial Found

A three-year trial found fewer new type 2 diabetes diagnoses on tirzepatide in adults with prediabetes and overweight or obesity. The FDA indication is separate.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Placebo group: who developed type 2 diabetes?1-hour glucose test15%fasting glucose37%HbA1c19%Among participants flagged by each test.

The three-year analysis enrolled adults with prediabetes and overweight or obesity (n = 1,032) [2]. The different approved uses of Zepbound and Mounjaro matter when a clinician considers why to prescribe tirzepatide. The trial does not establish that everyone with prediabetes should take it.

What happened during and after treatment

At 176 weeks, 1.3% of the pooled tirzepatide groups had developed type 2 diabetes, compared with 13.3% on placebo [2]. After 17 weeks off treatment, cumulative figures were 2.4% and 13.7%. Studies of weight after stopping a GLP-1 address a related question about how treatment effects change after withdrawal. This trial followed participants for only 17 weeks after treatment stopped.

How well did glucose tests predict progression?

A follow-up analysis examined three test thresholds among trial participants who had already qualified as having prediabetes [1]. In the placebo group, diabetes developed in 15% of those flagged by the one-hour glucose test. The figures were 37% for fasting glucose and 19% for HbA1c. The one-hour threshold captured more eventual cases, but it also flagged more people who did not develop diabetes. These estimates apply to this trial population and its thresholds.

What to discuss with a clinician

US diabetes guidance recommends structured prevention programs for adults with overweight or obesity at high risk of type 2 diabetes [3]. It also recognizes the role of weight-management medications when appropriate. Zepbound’s FDA label covers weight management in eligible people and obstructive sleep apnea in certain adults with obesity [4]. Prediabetes itself is outside those indications.

Frequently asked

Did tirzepatide reduce new type 2 diabetes diagnoses?
By week 176, 1.3% of pooled tirzepatide participants and 13.3% on placebo had developed type 2 diabetes. Participants had prediabetes and overweight or obesity.
What happened after treatment stopped?
Seventeen weeks after treatment stopped, the cumulative figures were 2.4% and 13.7%. The trial did not assess outcomes further out.
Is Zepbound approved for prediabetes?
Prediabetes is outside the FDA label. Zepbound is approved for weight management in eligible people and for certain adults with obstructive sleep apnea and obesity.

Sources

  1. [1] Galindo RJ, Dimitriadis GK, Stefanski A, et al. (2026). Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis Journal of the Endocrine Society. PMID 42656588
  2. [2] Jastreboff AM, et al. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention New England Journal of Medicine. PMID 39536238
  3. [3] American Diabetes Association Professional Practice Committee (2026). Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026 Diabetes Care. Source
  4. [4] Eli Lilly and Company (2026). Zepbound prescribing information, section 1 DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence